君實生物(688180.SH):擬收購及增資取得至善唯新6.5598%股權 佈局新一代治療技術
格隆匯 2 月 8日丨君實生物(688180.SH)公佈,公司擬出資606.3812萬元收購景誠(成都)股權投資基金合夥企業(有限合夥)(“景誠成都”)所持有的四川至善唯新生物科技有限公司(“至善唯新”)1.5957%股權。
上述交易完成後,公司擬最高出資3393.6188萬元參與認購至善唯新的增資擴股,此次增資全部完成後,公司將持有至善唯新6.5598%股權。
至善唯新擁有穩定成熟的三質粒重組腺相關病毒(Recombinant Adeno-associated Virus, rAAV)生產平台。rAAV具有免疫原性低、轉染效率高、表達時效長的特點,是進行外源基因轉導和表達研究的優良載體。且至善唯新的基因藥物優化經驗豐富,正在積極開發擁有更高活力的基因藥物。基因治療針對單/多基因缺陷疾病有獨特的治療潛力,相比抗體藥物、小分子藥物可能實現療效更長、依從性更佳等優勢,是至善唯新佈局的重要疾病治療技術方向。至善唯新的主營業務為醫藥技術開發、技術諮詢(不含醫療衞生活動)、技術轉讓,此次交易系公司佈局新一代治療技術的戰略安排,與公司主營業務具有協同性。
此次關聯交易系公司與上海檀英、上海樂永、上海乾剛(“領投方”)等專業投資機構共同投資至善唯新,將促進公司與同行業其他公司加強合作,充分利用行業內優質資源,符合公司長期發展戰略,不會影響公司正常的生產經營活動,預計不會對公司經營業績產生重大不利影響,符合公司及全體股東利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.